|
1Matsuda T, Saika K: Comparison of time trends in prostate cancer incidence (1973-2002) in asia, from cancer incidence in five continents, vols iv-ix. Jpn J Clin Oncol 2009;39:468-469. 2Matsuda T, Saika K: Comparison of time trends in prostate cancer incidence (1973-1997) in east asia, europe and USA, from cancer incidence in five continents vols iv-viii. Jpn J Clin Oncol 2007;37:556-557. 3Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916. 4Luboldt HJ, Bex A, Swoboda A, Husing J, Rubben H: Early detection of prostate cancer in germany: A study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff. Eur Urol 2001;39:131-137. 5Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M: Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men. J Urol 2000;163:1144-1148; discussion 1148-1149. 6Kumar A, Godoy G, Taneja SS: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy. Can J Urol 2009;16:4655-4659. 7Mian BM, Naya Y, Okihara K, Vakar-Lopez F, Troncoso P, Babaian RJ: Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology 2002;60:836-840. 8Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW: Analysis of percent free prostate-specific antigen (psa) for prostate cancer detection: Influence of total psa, prostate volume, and age. Urology 1996;48:55-61. 9Di Donna A, Bazzocchi M, Guerra UP, Bendini M, De Biasi F, Caminiti F, Delendi M: [the role of the absolute value and "Density" Of the prostate-specific antigen estimated echographically in the selection of patients to undergo a biopsy in suspected prostatic carcinoma. A comparison between psa, palpation and echography in 95 patients undergoing echo-guided endorectal prostatic biopsy]. Radiol Med 1993;85:84-89. 10Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF: Methods of calculating prostate-specific antigen velocity. Eur Urol 2007;52:1044-1050. 11Levine MA, Ittman M, Melamed J, Lepor H: Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998;159:471-475; discussion 475-476. 12Stewart CS, Leibovich BC, Weaver AL, Lieber MM: Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001;166:86-91; discussion 91-82. 13Rabets JC, Jones JS, Patel A, Zippe CD: Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol 2004;172:94-97. 14Sajadi KP, Kim T, Terris MK, Brown JA, Lewis RW: High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates. Urology 2007;70:691-695. 15Stav K, Leibovici D, Sandbank J, Lindner A, Zisman A: Saturation prostate biopsy in high risk patients after multiple previous negative biopsies. Urology 2008;71:399-403. 16Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T, Schlomm T, Huland H, Karakiewicz PI: High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006;50:498-505. 17Yang CR, Su CK, Chiu KY, Ho HC, Ou YC, Cheng CL, Lee H: Free / total prostate specific antigen ratio for prostate cancer detection: A prospective blind study. Anticancer Res 2005;25:2439-2443. 18Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC, Marberger M: Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 1998;160:411-418; discussion 418-419. 19Shen J-t, Guo W-h, Xin X-y, Jia Z-j, Xu P, Shi M: Roc curve analysis of fpsa/tpsa and pasd for prostate cancer with tpsa in diagnostic gray zone Journal of Modern Laboratory Medicine 2007;5:64-66. 20Vickers AJ, Savage C, O''Brien MF, Lilja H: Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009;27:398-403. 21Akobeng AK: Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr 2007;96:644-647. 22Fluss R, Faraggi D, Reiser B: Estimation of the youden index and its associated cutoff point. Biom J 2005;47:458-472. 23Perkins NJ, Schisterman EF: The inconsistency of "Optimal" Cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163:670-675.
|